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Stress and glucocorticoids (GCs) have universally been considered to be anti-inﬂammatory, however in
recent years, stress and GCs have been found to exert permissive effects (immunological priming) on
neuroinﬂammatory processes. This phenomenon of priming is characterized by prior stress or GC
exposure potentiating the neuroinﬂammatory response to a subsequent immune challenge. A consid-
erable body of evidence is discussed here that supports this permissive effect of stress and GCs.
In light of this evidence, a mechanism of neuroinﬂammatory priming is proposed involving a signal
cascade in the brain involving danger-associated molecular patterns (HMGB-1) and inﬂammasomes
(NLRP3), which results in an exaggerated or ampliﬁed neuroinﬂammatory response and subsequently,
the ampliﬁcation of the physiological and behavioral sequelae of this response (i.e. sickness). Finally, we
explore the notion that stressor-induced sensitization of the neuroimmune microenvironment may
predispose individuals to psychiatric disorders, in which exaggerated innate immune/inﬂammatory re-
sponses in the brain are now thought to play a key role.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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Exaggerated innate immune/inﬂammatory responses in the
brain are now thought to be a common core in the etiology of
numerous psychiatric disorders such as depression, PTSD and bi-
polar disorder (Jones and Thomsen, 2013). Seemingly unrelated to
neuroinﬂammation, the experience of life stressors is a predis-
posing factor in the development of psychiatric disorders (Kessler,
1997). However, the clinical literature contains numerous in-
stances in which stress predisposes individuals to inﬂammatory
disorders such as cardiovascular disease (Albus, 2010), which have
a high comorbidity with psychiatric conditions that include
depression (Sansone and Sansone, 2008). Indeed, recent evidence
from several laboratories, including our own, suggests that
stressors sensitize or prime the neuroinﬂammatory response to
subsequent pro-inﬂammatory challenges, thereby providing a
mechanism that can link the impact of stressors and a pivotal role
for neuroinﬂammatory processes in the development of psychiatric
disorders.
The central notion explored here is that exposure to stressors
can induce a vulnerable phenotype characterized, in part, by a
sensitized neuroimmune microenvironment. Thus, prior stress can
lead to a potentiated neuroinﬂammatory cascade upon exposure to
pro-inﬂammatory challenges that include bacterial or viral infec-
tion and sterile injury. This exaggerated neuroinﬂammatory
response can then manifest as changes in cognitive (e.g. memory),
affective (e.g. mood), sensory (e.g. pain) and vegetative (e.g. sleep
and eating) endophenotypes, typically observed in a spectrum of
psychiatric disorders. Several neuroimmunemechanisms, bywhich
stress sensitizes/primes the neuroinﬂammatory response to pro-
inﬂammatory challenges, have been characterized in recent years.
First, a brief overview of neuroinﬂammatory processes will be
provided as a basis for exploring mechanisms of neuro-
inﬂammatory priming.
2. Neuroinﬂammatory processes and microglia
Neuroinﬂammatory processes are characterized, in large part,
by the activation of CNS innate immune effector cells including
microglia, which secrete an array of inﬂammatory mediators
including pro-inﬂammatory cytokines, chemokines, prostaglandins
and reactive oxygen/nitrogen species (Ransohoff and Perry, 2009).
When elaborated under a variety of neuropathological conditions,
including neurodegeneration, brain trauma, ischemia and seizure,
thesemediators induce the hallmarks of neuroinﬂammation, which
may include recruitment of peripheral leukocytes into the CNS
(Graeber et al., 2011). Of note, peripheral infection or immune
challenge also is capable of inducing a neuroinﬂammatory response
in the brain (McCusker and Kelley, 2013). For example, peripheral
injection of lipopolysaccharide (LPS), a non-infectious component
of the cell wall of gram-negative bacteria (e.g. E. coli), is commonly
used as an immunogenic stimulus to induce a pro-inﬂammatory
response in peripheral biological compartments or organs such as
liver, spleen, serum or peritoneum. As a result of pathogen expo-
sure or immune challenge with agents such as LPS, peripheral
myeloid cells, such as splenic macrophages or liver Kupffer cells,
secrete pro-inﬂammatory cytokines, which then signal the brain
through several well-characterized neural and humoral pathways
connecting the immune system with the CNS (Maier, 2003). A
neural cascade initiated by immune-to-brain signaling then leads
to the production of pro-inﬂammatory cytokines and other in-
ﬂammatory products by microglia and other CNS innate immune
cells as if these cells had been directly exposed to the pathogenic
agent (McCusker and Kelley, 2013). It should be noted that pe-
ripheral pathogens are typically excluded from entering the brainand directly activating CNS innate immune cells by the blood brain
barrier (Banks, 2015). Thus, cytokine mediated immune-to-brain
signaling is a pivotal immunologic process whereby the immune
system communicates to the brain that infection or injury has
occurred in the periphery. Once the CNS is alerted of an immuno-
logic threat to the organism, the subsequent neuroinﬂammatory
response engages neural mechanisms that mediate physiological
and behavioral modiﬁcations, also known as the sickness response,
which are key to effective host defense (Dantzer et al., 2008).
Interestingly, aspects of the sickness response resemble aspects of
several mood disorders, most notably major depression (Dantzer,
2009), a theme we review in section 3.
2.1. Microglia function and activation states
As noted above, microglia are key effectors of neuro-
inﬂammatory processes and thus here we will brieﬂy describe the
physiological aspects of microglia function that are relevant for
understanding the role of this CNS innate immune cell in stress-
induced neuroinﬂammatory priming. Microglia are mononuclear
phagocytes that occupy the brain parenchyma and are ontogenet-
ically distinct from other CNS mononuclear phagocytes including
meningeal, choroid plexus, and perivascular macrophages, which
reside outside the brain parenchyma (Katsumoto et al., 2014). It is
important to note that these macrophage subtypes also serve a
critical role in the brain's innate immune response and may
contribute to the processes under discussion here (Schiltz and
Sawchenko, 2003). Unlike other CNS macrophages, microglia are
maintained in the adult CNS independent of circulating blood
monocytes and are thought to self-renew from progenitor cells in
the CNS (Katsumoto et al., 2014). Microglia perform several critical
functions in the CNS including immunosurveillance for pathogens,
cellular debris, apoptotic cells, and alterations in neuronal pheno-
type (Ransohoff and Cardona, 2010). Recent reviews suggest that
microglia may enter a spectrum of activation states (Mosser and
Edwards, 2008; Rivest, 2009), which are characterized by varying
blends of immunophenotypes and cytokine proﬁles. Of particular
relevance here, a primed activation state may be induced in
microglia under several neuroinﬂammatory conditions (Perry et al.,
2007) that include exposure to psychological stressors and stress
hormones such as glucocorticoids (Frank et al., 2015a). Microglia
are considered primed if, upon exposure to a pro-inﬂammatory
stimulus such as LPS, the pro-inﬂammatory cytokine response of
microglia is potentiated beyond normal. For example, we have
found that prior exposure to a severe acute stressor potentiates the
pro-inﬂammatory response of microglia to a subsequent immune
challenge (i.e. LPS) ex vivo (Frank et al., 2007). A primed state has
been associated with morphological changes such as shrunken
processes and increased soma size, as well as immunophenotypic
changes such as increased expression of surface antigens including
major histocompatibility class II (MHCII) (Norden et al., 2015).
Importantly, a primed activation state may not involve increased
pro-inﬂammatory output. However, it is unclear whether a primed
activation state involves uniform changes in microglia morphology
and immunophenotype. This primed state of activation can be
conceptualized as a ‘readiness’ state because, when in this state,
microglia will rapidly respond to inﬂammatory stimuli with exag-
gerated production of pro-inﬂammatory cytokines.
2.2. Toll-like receptors (TLRs)
Microglia express an array of receptors that allow microglia to
rapidly mount an immune response to exogenous or endogenous
immunological threats (Rivest, 2009). At least 50 cell surface anti-
gens distinguish mononuclear phagocytes from other cell types
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are thought to play a pivotal role in stress-induced neuro-
inﬂammatory priming (Frank et al., 2015b). Microglia express many
of the TLRs characterized in peripheral immune cells (Carpentier
et al., 2008). Cells of the innate immune system recognize micro-
bial products via germ line-encoded receptors that recognize gen-
eral molecular patterns or motifs that characterize classes of
pathogens (Pathogen Associated Molecular Patterns; PAMPs
(Janeway and Medzhitov, 2002)). For this reason, receptors that
recognize PAMPs have been termed pattern recognition receptors
(PRRs). Of these PRRs, TLRs are the most extensively characterized
(Barton and Kagan, 2009). TLRs are a family of highly conserved
membrane or cytosolic (dependent on TLR subtype) proteins that
transduce signals through a family of cytosolic Toll adapter proteins
that link to downstream signaling cascades (Barton and Kagan,
2009). The ligation of many of the TLR family members ulti-
mately activates the transcription factor, nuclear factor of kappa
light polypeptide gene enhancer in B-cells (NF-kB), as well as other
transcription factors (Salminen et al., 2008), and NF-kB activation is
viewed as key to the inﬂammatory effects of TLR ligation (Salminen
et al., 2008). TLR2 and TLR4 have been the most intensively studied
PRRs within the CNS, and are expressed onmicroglia (Aravalli et al.,
2007). They are sometimes reported to be present on astrocytes
and sometimes absent, and are typically reported to be absent on
neurons (Lehnardt et al., 2003). TLR4 recognizes the LPS motif
present in the cell membrane of gram-negative bacteria, while
TLR2 recognizes lipoteichoic acid that characterizes gram-positive
bacteria (Kawai and Akira, 2007).
Although TLRs were ﬁrst studied as receptors for microbial
products that then activate immune cells such as macrophages and
dendritic cells, thereby initiating host defense against infection,
TLRs have also been found to recognize endogenous molecular
patterns. Over the past several decades it has become clear that
peripheral immune responses are initiated by a number of condi-
tions that do not involve pathogen entry into the body such as a
sterile bone break (Chen and Nunez, 2010). These conditions have
been summarized as “danger” (Bianchi and Manfredi, 2009), and
the necessary implication is that these dangers must lead to the
release of endogenousmolecules that act to initiate innate immune
responding. A number of these molecules have been characterized
and have been collectively called danger-associated molecular
patterns (DAMPs) or alarmins (Bianchi, 2007). Interestingly, one of
these DAMPs, high mobility group box 1 protein (HMGB-1) is
recognized by TLR2 and TLR4 (Yang et al., 2013) and is present in
brain (Fang et al., 2012). HMGB-1 is thought to alert innate immune
cells to a variety of internal conditions such as cellular stress,
damage or necrosis (Kawai and Akira, 2010). Of note, TLR2 and TLR4
recognize other DAMPs including histones, heat shock proteins and
S100 proteins (Venereau et al., 2015), which may play a role in
neuroinﬂammatory priming. However, HMGB1 is of particular in-
terest here because of its direct role in priming of inﬂammasome
signaling (See section 2.4.)
2.3. HMGB-1 and TLR signaling
Our interest has centered on the DAMP HMGB-1, which stem-
med from our initial ﬁnding that pharmacologic blockade of TLR2
and TLR4 during stress exposure abrogates stress-induced priming
of the neuroinﬂammatory response to a subsequent immune
challenge (Weber et al., 2013) (see Section 4.2.). HMGB-1 is a
ubiquitous nuclear DNA binding protein, which under normal
conditions, is not present in the extracellular space (Kang et al.,
2014). However, under necrotic conditions, HMGB-1 is passively
released into the extracellular milieu to serve as an inﬂammatory
signal (Scafﬁdi et al., 2002). As noted above, TLR2 and TLR4mediatethe pro-inﬂammatory effects of HMGB-1, although some recent
studies now suggest that the pro-inﬂammatory effects of HMGB-1
are mediated predominately through TLR4 (Yang et al., 2013). The
receptor for advanced glycation end products (RAGE) and the
chemokine receptor CXCR4 are thought tomediate the chemotactic
function of HMGB-1 (Yang et al., 2013). Interestingly, immuno-
competent cells also have the unique ability to actively release
HMGB-1 in the absence of cell death (Bonaldi et al., 2003).
There are three distinct forms of HMGB-1 characterized by
post-transcriptional modiﬁcation of the redox state of three crit-
ical cysteine residues (C23, C45, and C106). Fully reduced (fr)
HMGB-1 is the predominant form that occurs under non-oxidizing
conditions. fr-HMGB-1 has chemotactic properties produced by
the formation of a hetero-complex with the chemokine CXCL12,
which then signals through the chemokine receptor CXCR4
(Schiraldi et al., 2012). The pro-inﬂammatory form occurs under
increased oxidizing conditions, in which a disulﬁde bridge forms
between C23 and C45 (disulﬁde (ds) HMGB-1). This redox form
interacts with TLR4 to induce synthesis and secretion of pro-
inﬂammatory cytokines (Antoine et al., 2014). Finally, the fully
oxidized form of HMGB-1 has no known biological activity
(Venereau et al., 2012).2.4. TLR4, the NLRP3 inﬂammasome and IL-1b
The formation and secretion of IL-1b is a critical step in the
neuroinﬂammatory cascade and IL-1b has been termed the “master
regulator” of neuroinﬂammation (Basu et al., 2004), given its
pleiotropic role in the induction of central inﬂammatory processes
as well as its critical role in the manifestation of the sickness
response (Goshen and Yirmiya, 2009). Thus, the production, pro-
cessing and signaling of IL-1b is under tight regulation (Dinarello,
2011). IL-1b is transcribed as a larger pro-hormone, pro-IL-1b,
and pro-IL-1bmust be cleaved by caspase-1 to form the biologically
active, mature form of IL-1b.
The process of cleaving pro-IL-1b typically requires the forma-
tion and activation of an inﬂammasome, most often the nucleotide-
binding domain and leucine-rich repeat containing family, pyrin
domain containing 3 (NLRP3) inﬂammasome, an intracellular
multiprotein complex that mediates processing and maturation of
IL-1b via activation of caspase-1 (Martinon et al., 2009). Impor-
tantly, signaling at TLR4 initiates an intracellular signaling cascade
to activate the immune-related transcription factor NF-kB (Kawai
and Akira, 2010), which is a critical step in the formation of the
NLRP3 inﬂammasome. The NLRP3 inﬂammasome is particularly
interesting because of 1) its unique functional requirements that
include a priming step and an activation step (Hornung and Latz,
2010) and 2) the role of glucocorticoids in priming of the NLRP3
inﬂammasome (Busillo and Cidlowski, 2013) (see section 4.4.).
Priming occurs in response to a stimulus that signals, in part,
through TLR4 to increase the expression of the sensor protein
NLRP3 to a critical threshold (Latz et al., 2013) (Fig. 1). Interestingly,
HMGB-1 has been reported to increase NLRP3 mRNA and protein
(Xiang et al., 2011) suggesting that HMGB-1 may function as a
priming stimulus of the NLRP3 inﬂammasome. Subsequently, a
second activating signal such as adenosine triphosphate (ATP) is
then required to form the NLRP3 inﬂammasome complex with the
adapter protein ASC, which then recruits and cleaves pro-caspase-1
into mature caspase-1 (Latz et al., 2013). In turn, caspase-1 cleaves
pro-IL-1b into mature IL-1b. It is to be noted that other pro-
inﬂammatory cytokines, such as IL-6 and TNFa, are not under this
type of tight regulation and are not inﬂammasome dependent
(Kumar et al., 2011).
Fig. 1. Priming and activation of the NLRP3 inﬂammasome. The canonical pathway of NLRP3 inﬂammasome activation is thought to require a two-step process. An initial priming
step involves signaling through pattern recognition receptors such as TLR4 and subsequent activation of NF-kB, which then drives transcription of NLRP3. Once NLRP3 mRNA/
protein is increased to a critical threshold, the cell is considered primed, but pro-inﬂammatory cytokine output is not increased. Upon exposure to a second activating signal such as
ATP, NLRP3 forms a complex with ASC. This complex recruits pro-caspase-1, which is then converted to mature caspase-1. Caspase-1 is the rate-limiting enzyme in the conversion of
pro-IL-1b to mature IL-1b. Once formed, mature IL-1b is then released via an unconventional pathway independent of the Golgi apparatus. Abbreviations: HMGB-1 (high mobility
group box-1); NLRP3 (nucleotide-binding domain and leucine-rich repeat containing family, pyrin domain containing 3); TLR4 (Toll-like receptor 4); NF-kB (nuclear factor of kappa
light polypeptide gene enhancer in B-cells); ATP (adenosine triphosphate); P2X7R (purinergic receptor P2X, ligand gated ion channel, 7); ASC (apoptosis-associated speck-like
protein containing a caspase recruitment domain); IL (interleukin).
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While pro-inﬂammatory cytokines are key mediators sub-
serving critical immune functions of microglia and other CNS
innate immune cells, these mediators of neuroinﬂammation also
orchestrate a constellation of physiological and behavioral modiﬁ-
cations known as the sickness response (Dantzer et al., 2008).
Beyond the scope of the present review, IL-1b is a particularly
important mediator of the sickness response and has been the
subject of several in-depth reviews (for example see review by
(Goshen and Yirmiya, 2009)). However, it should be noted that
other pro-inﬂammatory cytokines including TNFa play a role in the
sickness response to pro-inﬂammatory stimuli (Dantzer et al.,
2008). This response includes cognitive (memory), affective
(mood), vegetative (sleep and eating), sensory (pain) and physio-
logical (fever) changes, which play an adaptive role in an organ-
ism's host defense against infection, trauma, and injury (Dantzer,
2009). Of note, there is a remarkable similarity between the hall-
marks of the sickness response and clinical endophenotypes typi-
cally observed in several psychiatric disorders including major
depression and anxiety disorders. For example, anhedonia is a
symptom typically observed in major depression and is also a
hallmark of the sickness response to infection or injury (Dantzer
et al., 2008). Indeed, a considerable number of ﬁndings suggest
that inﬂammatory processes may play a role in the etiology of
major depression (Raison and Miller, 2013). Moreover, some of the
strongest evidence implicating pro-inﬂammatory cytokines in the
pathogenesis of depression stems from studies demonstrating that
treatment with pro-inﬂammatory agents is sufﬁcient to induce
depressive symptoms (Miller et al., 2009). Of particular relevance
here, prior exposure to acute and chronic stressors potentiates the
sickness response to subsequent pro-inﬂammatory challenges.
Further, prior exposure to stress induces a primed microglialimmunophenotype such that the neuroinﬂammatory response to a
subsequent inﬂammatory challenge is also potentiated (See section
4.2.). Therefore, we propose that stress-induced priming of neu-
roinﬂammatory processes may serve to predispose individuals to a
heightened neuroinﬂammatory response as well as the neural/
behavioral sequelae of that response if exposed to a subsequent
pro-inﬂammatory insult. In doing so, this neuroinﬂammatory
priming effect of stress may function as an etiological risk factor in
the development of major depression or other psychiatric disorders
in which inﬂammatory processes have been implicated in disease
pathogenesis (Jones and Thomsen, 2013).
4. Mechanisms of neuroinﬂammatory priming
4.1. Acute inﬂammatory responses to a stressor
Exposure to an acute stressor induces a rapid and brief (2e6 h)
increase of pro-inﬂammatory cytokines in stress-reactive areas of
the brain, including the hypothalamus and hippocampus (Johnson
et al., 2005). As a result, acute exposure to a stressor also induces
physiological and behavioral sickness response changes that are
similar to those produced by a peripheral immune challenge. A
stressor as seemingly minor as placing a rat in a novel environment
produces fever and impairs contextual fear conditioning (LeMay
et al., 1990; Pugh et al., 1999). Other typical sickness responses
have also been observed after stress exposure, including decreased
body weight, food and saccharine consumption, and social explo-
ration (Christianson et al., 2008; Johnson et al., 2003). It is known
that these sickness responses result from the cytokine increases
because blockade of cytokine receptors in the brain and/or cytokine
synthesis blocks or reduces changes in these responses (Goshen
and Yirmiya, 2009). The rapid increase in the pro-inﬂammatory
cytokine and behavioral response to a stressor is due, at least in
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associated release of catecholamines (Johnson et al., 2005).
Norepinephrine is a fundamental component of the ﬁght/ﬂight
response that modulates physiological responses to a stressful
event. Another major element of norepinephrine is to relay infor-
mation to the immune system. In the CNS, stimulation of beta-
adrenergic receptors increases IL-1b mRNA expression in glial
cells (Johnson et al., 2005; Maruta et al., 1997). Moreover, periph-
eral administration of beta-adrenergic receptor antagonists prior to
stress prevents subsequent brain cytokine responses and the
related behaviors controlled by these cytokines (Blandino et al.,
2009; Hanke et al., 2012; Johnson et al., 2005; Wohleb et al., 2011).
4.2. Neuroinﬂammatory priming
Exposure to a stressor not only produces a transient neuro-
inﬂammatory response, but also alters how an organism responds
to a subsequent inﬂammatory challenge for a period of time after
the stress exposure has ended. Several studies have found that prior
exposure to a potent acute or chronic stressor potentiates the
neuroinﬂammatory and microglial pro-inﬂammatory response, as
well as the sickness response, to a subsequent immune challenge
(de Pablos et al., 2014; de Pablos et al., 2006; Espinosa-Oliva et al.,
2011; Frank et al., 2007, 2012; Johnson et al., 2002, 2003, 2004;
Munhoz et al., 2006; Weber et al., 2013, 2015; Wohleb et al., 2012;
Wohleb et al., 2011). Importantly, in these studies, neuro-
inﬂammatory and microglial priming was induced using several
types of stressors including chronic social defeat, chronic unpre-
dictable mild stress and acute inescapable tail shock. The paradigm
we employ involves 100 brief tailshocks that the subject, typically a
rat, cannot escape (inescapable tailshock; IS). Control rats are left
undisturbed in their home cage (home cage controls; HCC). 24 h
after IS, cytokine levels in the brain are at control levels (Johnson
et al., 2003). However, when an immunogenic agent such as LPS
is administered, the pro-inﬂammatory cytokine response (IL-1b, IL-
6, TNFa) in several brain regions (hypothalamus, hippocampus, and
cortex) is potently exaggerated compared with HCC subjects that
were administered the same immune challenge. As a result, phys-
iological and behavioral processes that are controlled by these
brain cytokines are also changed. For example, LPS-induced fever,
corticosterone, adrenocorticotropic hormone, and decreased loco-
motor activity are all potentiated by prior exposure to IS (Johnson
et al., 2003). It should be noted that the potentiated neuro-
inﬂammatory response to an immune challenge typically lasts 4e6
days after IS exposure (Johnson et al., 2002). This period of neu-
roinﬂammatory sensitization can be conceptualized as a period of
vulnerability during which an organism is susceptible to the pro-
duction of heightened neuroinﬂammatory processes, if exposed to
an immune challenge. It should also be noted that the duration of
this period of vulnerability is likely inﬂuenced by several factors,
including the nature, intensity and duration of the stressor. In
humans, understanding how stress predisposes individuals to
develop psychiatric disorders is a key question that has only been
partially answered. Given the link between psychiatric disorders
and neuroinﬂammatory processes, our laboratory has been inter-
ested in understanding the central mechanism(s) by which expo-
sure to a stressor impacts the neuroinﬂammatory environment.
4.3. Role of microglia
To begin to explore this question, we ﬁrst examined the primary
innate immune cell in the brain, microglia. One limitation of
measuring cytokines in brain tissue is that the cellular source is
unknown, as microglia, astrocytes, endothelial cells, neurons as
well as other myeloid cells produce cytokines (Basu et al., 2004). Inorder to address this issue, our laboratory developed a procedure to
isolate and study microglia ex vivo (Frank et al., 2006). As noted
above, quiescent or surveillant microglia express low levels of the
cell surface antigen MHCII, which is rapidly upregulated when
microglia are activated (Aloisi, 2001) and is indicative of a primed
activation state (Perry, 2004). Exposure to IS increased both mRNA
and protein expression of MHCII on hippocampal microglia for at
least 24 h after termination of the stressor. However, exposure to IS
alone had no effect on hippocampal IL-1b mRNA levels 24 h later
(Frank et al., 2007). That is, although MHCII was upregulated on
microglia, the cells were not producing IL-1b, suggesting that
exposure to a stressor induces a primed state in microglia. Indeed,
whenmicroglia were isolated from rats that were exposed to IS and
stimulated with LPS ex vivo, the pro-inﬂammatory cytokine
response was signiﬁcantly increased compared with HCC microglia
stimulated with LPS (Frank et al., 2007). A study by Wohleb and
colleagues reported similar ﬁndings using repeated social defeat as
a stressor (Wohleb et al., 2011). Mice were given 6 consecutive days
of social defeat stress and whole brain microglia were isolated and
treated with LPS ex vivo. Prior exposure to social defeat potentiated
the microglial pro-inﬂammatory response to LPS compared to the
pro-inﬂammatory response of microglia isolated from HCC mice.
Taken together, these ﬁndings suggest that acute and chronic
stressors prime microglia such that exposure of microglia to a
subsequent immune challenge results in an exaggerated pro-
inﬂammatory response. Further, these ﬁndings imply that
stressors may induce the release of a signaling molecule in the
brain that modulates the immunophenotype of microglia, thereby
inducing a primed activation state. Towards addressing this possi-
bility, we focused on the role of stress-induced glucocorticoids
(GCs), which on the face of it seems counter-intuitive given the
preponderance of evidence showing that GCs are largely anti-
inﬂammatory (Boumpas et al., 1993). But, as we detail in section
4.4, GCs have also been found to have paradoxical effects, which are
inconsistent with the anti-inﬂammatory properties typically
attributed to GCs.
4.4. Stress, GCs and neuroinﬂammatory priming
Stress (Webster Marketon and Glaser, 2008) and GCs (Boumpas
et al., 1993) have been historically regarded to be anti-
inﬂammatory, and this concept has been a bedrock principle until
very recently. It has never been clear how inhibition of innate im-
mune inﬂammatory responses by GCs would be adaptive during a
ﬁght/ﬂight emergency as these are periods of increased risk for
infection and injury. This “conundrum” has provoked numerous
theoretical attempts at a resolution (Frank et al., 2013; Munck et al.,
1984). Moreover, a fair number of clinical trials have reported that
GC therapy is not always anti-inﬂammatory and sometimes pro-
duces paradoxical results with the relevant condition being exac-
erbated rather than alleviated (Rutgeerts, 2001). Current thinking
about the role of stress in the development of psychiatric disorders
has also likely been constrained by the notion that stress must be
anti-inﬂammatory, rather than pro-inﬂammatory. However, recent
studies from our laboratory as well as several others now suggest
that stress-induced GCs can actually promote or prime neuro-
inﬂammatory processes to subsequent immune challenges. Beyond
the scope of the present review, it is important to note that a
considerable number of studies have found that stress-induced
noradrenergic processes as well as modulation of immune cell
trafﬁcking to the brain play a role in stress-induced neuro-
inﬂammatory priming (Wohleb et al., 2014), which may play a role
in the processes of neuroimmune priming under discussion here.
A number of studies have found that pharmacological blockade
of GC signaling during acute or chronic stress exposure ameliorates
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mune challenge (de Pablos et al., 2014; de Pablos et al., 2006;
Espinosa-Oliva et al., 2011; Frank et al., 2012; Munhoz et al.,
2006). Moreover, we found that pharmacological (RU486) and
surgical (adrenalectomy) blockade of GC signaling during stress
exposure abrogated the stress-induced potentiation of the micro-
glia pro-inﬂammatory response to an immune challenge (LPS)
ex vivo (Frank et al., 2012). These ﬁndings suggest that the stress-
induced rise in GCs leads to a shift in the activation state of
microglia from surveillant to primed. While these studies demon-
strated the necessity of GC signaling in stress-induced neuro-
inﬂammatory priming (de Pablos et al., 2014; de Pablos et al., 2006;
Espinosa-Oliva et al., 2011; Frank et al., 2012; Munhoz et al., 2006),
a number of studies have also found that exogenous GC treatment is
sufﬁcient to prime neuroinﬂammatory processes as well as the
microglial pro-inﬂammatory response ex vivo.
We found that acute administration of corticosterone (CORT)
potentiated the neuroinﬂammatory response to LPS that was
administered 24 h after CORT injection (Frank et al., 2010). More-
over, we found that hippocampal microglia isolated 24 h after CORT
injection and challenged with LPS ex vivo also exhibited a poten-
tiated pro-inﬂammatory response to LPS. Interestingly, if CORT was
administered 1 h after LPS, the neuroinﬂammatory response to LPS
was suppressed. It should be noted that the dose of CORT employed
in this study was found to induce a pattern in serum CORT con-
centrations that mimics that produced by inescapable tailshock
(Fleshner et al., 1995). Subsequent studies have also found that
chronic CORT administration primes the neuroinﬂammatory
response as well as the ex vivo microglial pro-inﬂammatory
response to a subsequent immune challenge (Frank et al., 2014;
Munhoz et al., 2010). Although the mechanism(s) by which CORT
primes microglia is still under investigation, Munhoz and col-
leagues found that prior CORT exposure potentiates the LPS in-
duction of several signal transduction pathways including the NF-
kB pathway (Munhoz et al., 2010). Similarly, we have found that
chronic CORT treatment dose dependently increased NLRP3 gene
expression as well as NF-kB inhibitor a, which is induced by NF-kB
activation (Sun et al., 1993). Taken together, these studies suggest
the possibility that GCs activate the NF-kB pathway, thereby leading
to up-regulation of NLRP3 expression and priming of the NLRP3
inﬂammasome. Indeed, Busillo and colleagues have found that GCs
increase NLRP3 expression in macrophage cell lines as well as
potentiate the macrophage pro-inﬂammatory response to a sub-
sequent immune challenge (Busillo et al., 2011). We have recently
replicated this effect of GCs on NLRP3 expression in primary
microglia (unpublished observations). However, it is unclear from
these ﬁndings how GCs could directly induce NLRP3 or for that
matter activate NF-kB. A likely possibility is that GCs prime neu-
roinﬂammatory processes via induction/release of danger signals,
such as HMGB-1, in the brain. HMGB-1 may then target TLR4 on
microglia to activate NF-kB and increase NLRP3 expression, thereby
priming the NLRP3 inﬂammasome. To begin exploring this notion,
we examined the role of HMGB-1 in neuroinﬂammatory priming.
4.5. HMGB-1 as a neuroinﬂammatory priming signal
In order for microglia to be primed by stress, microglia must ﬁrst
receive a priming signal. Recent evidence implicates HMGB-1 as
one such signal. As noted above, our interest in HMGB-1 stemmed
from an initial investigation demonstrating that blockade of TLR2
and TLR4 during stress exposure abrogated stress-induced priming
of microglia (Weber et al., 2013). Given that TLR2 and TLR4 mediate
the pro-inﬂammatory effects of HMGB-1, we explored the possi-
bility that stress-induced HMGB-1 may play a role in neuro-
inﬂammatory priming. An initial investigation revealed that ISincreases HMGB-1 protein in the hippocampus (Weber et al., 2015).
Further investigation indicated that hippocampal microglia, iso-
lated immediately after stress exposure, secreted an increased
amount of HMGB-1 compared with microglia from control animals.
Importantly, cell viability did not differ between stress and control
groups suggesting that HMGB-1 was actively secreted by microglia
in the absence of cell death.
The ﬁnding that stress increased hippocampal HMGB-1
expression led us to explore whether HMGB-1 plays a causal role
in stress-induced priming of neuroinﬂammatory responses. To
explore whether HMGB-1 is necessary, a competitive HMGB-1
antagonist, boxA, was injected into the brain prior to stress expo-
sure. The blockade of HMGB-1 signaling in the brain prevented the
stress-induced priming of hippocampal microglia, that is, box A
administered prior to IS eliminated the exaggerated cytokine
response of microglia exposed to LPS ex vivo 24 h after IS (Weber
et al., 2015).
A key question concerns which redox form of HMGB-1 might
mediate stress-induced neuroinﬂammatory priming. Interestingly,
central administration of dsHMGB-1, but not frHMGB-1, primed
hippocampal microglia to LPS ex vivo (Weber et al., 2015). That is,
dsHMGB-1mimicked the effect of stress exposure onmicroglia and
is likely the form that is released during stress exposure to prime
microglia.
Another key issue concerns the mechanism by which dsHMGB-
1 primes microglia. One major difference between the 2 active
forms of HMGB-1 is their receptor targets. In this regard, dsHMGB-1
is a ligand for TLR4, while frHMGB-1 interacts with CXCR4 via
CXCL12 (Yang et al., 2013). Signaling at TLR4 initiates an intracel-
lular signaling cascade that activates the immune-related tran-
scription factor NF-kB (Kawai and Akira, 2007) and priming of the
NLRP3 inﬂammasome (Hornung and Latz, 2010), while CXCR4 ac-
tivates a variety of signaling pathways including ERK1/2, p38, SAPK/
JNK and mTOR, which are associated with calcium inﬂux, cell
mobility and survival (Ehtesham et al., 2013). Therefore, the ability
of dsHMGB-1 to prime microglia likely occurs via the TLR4/NF-kB
pathway.
Initially, we found that IS activates NF-kB and increases NLRP3
protein in the hippocampus, yet these changes were not associated
with alterations in IL-1b protein levels (Weber et al., 2015). This
ﬁnding would suggest that the NLRP3 inﬂammasome is ‘primed’
but not ‘active’ after exposure to the stressor. A similar effect was
observed by Pan and colleagues in the prefrontal cortex after
exposure to chronic mild stress (Pan et al., 2014). Moreover, NLRP3
inhibition during chronic mild stress prevented pro-inﬂammatory
cytokine increases (Liu et al., 2015). As noted in section 2.4,
HMGB-1 has been reported to increase NLRP3 mRNA and protein
(Xiang et al., 2011) and it has been argued that danger signals such
as HMGB-1 prime the NLRP3 inﬂammasome (Leemans et al., 2011).
This argument is supported by our ﬁnding that pharmacological
blockade of HMGB-1 signaling during stress exposure prevents
NLRP3 sensitization in microglia (Weber et al., 2015). Given that
NLRP3 priming can occur via TLR4 and TLR4 is a receptor target for
dsHMGB-1, we hypothesize that stress-induced dsHMGB-1, but not
frHMGB-1 primes the NLRP3 inﬂammasome. Thus, stressors, via
induction of increased secretion of dsHMGB-1, appear to prime the
inﬂammasome so that subsequent inﬂammatory challenges lead to
exaggerated pro-inﬂammatory mediators in the brain.
5. Summary
The effect of stressors on GCs, HMGB-1 and the NLRP3 inﬂam-
masome provides a potential mechanism by which stress exposure
primes neuroinﬂammatory processes (Fig. 2). Exposure to a
stressor can be conceptualized as ‘danger’. We propose that in
Fig. 2. A model of the neuroimmune mechanism of stress- and GC-induced ampliﬁcation of the neuroinﬂammatory response to immune challenges. We propose that a 2-step
process is required for stress/GC-induced potentiation of the neuroinﬂammatory response to a subsequent immune challenge. In the top panel (step 1), a mechanism of micro-
glia priming is proposed. Upon stress/GC exposure, increased levels of central GCs induce the extra-cellular release of HMGB-1 in the brain. In turn, HMGB-1 induces the upre-
gulation of NLRP3 expression in microglia and other CNS innate immune cells, most likely through the TLR4/NF-kB signaling pathway. With the upregulation of NLRP3, microglia are
considered primed. In the bottom panel (step 2), if a subsequent immune challenge occurs while microglia are primed, the ensuing neuroinﬂammatory and sickness response to
that challenge is potentiated compared to the “normal” neuroinﬂammatory response of surveillant microglia to the same immune challenge. Abbreviations: GC (glucocorticoid);
HMGB-1 (high mobility group box-1); NLRP3 (nucleotide-binding domain and leucine-rich repeat containing family, pyrin domain containing 3); TLR4 (Toll-like receptor 4); NF-kB
(nuclear factor of kappa light polypeptide gene enhancer in B-cells).
M.G. Frank et al. / Neurobiology of Stress 4 (2016) 62e7068response to stressors, GCs induce the release of HMGB-1 in the
brain, in part, by microglia. It should be noted that neurons are a
signiﬁcant source of HMGB-1 in the CNS (Fang et al., 2012) and thus
may be involved in the processes under discussion. Once released
into the extracellular space, HMGB-1, likely in the disulﬁde redox
state, signals microglia in an autocine/paracrine manner via TLR4.
Thus, binding at TLR4 activates NF-kB to synthesize NLRP3, and the
cell is now considered primed. In the event of a subsequent im-
mune challenge, formation of the NLRP3 inﬂammasome is poten-
tiated, resulting in greater caspase-1 activation and cleavage of pro-
IL-1b into the mature and bioactive IL-1b. IL-1b then initiates a
cascade of neuroinﬂammatory processes including the release of
other pro-inﬂammatory cytokines and inﬂammatory mediators.
Therefore, the net result is an exaggerated or ampliﬁed neuro-
inﬂammatory response and subsequently, the physiological and
behavioral sequelae of this cascade (i.e. sickness) are ampliﬁed.6. Future perspectives
While prior stress exposure is considered a predisposing factor
in the development of psychiatric disorders (Kessler, 1997), a key
question remains: why does stress lead to the development of
psychiatric disorders in some individuals, but not in others? A
number of factors mediating the relationship between stress and
psychiatric disorders have been proposed including individual
differences in biological, developmental, psychological and socio-
demographic factors (Hammen, 2005). Of these factors, sex differ-
ences are of particular relevance here insofar as females are more
susceptible to developing affective psychiatric disorders as well as
autoimmune disorders, which reﬂects the tendency of females to
display enhanced immune responses (Schwarz and Bilbo, 2012).Moreover, Bilbo and colleagues have found that pro-inﬂammatory
mediators are basally elevated in the brain of adult female rats
compared to males. Moreover, microglia of adult females exhibit an
activated phenotype (Schwarz et al., 2012). These ﬁndings suggest
that females may be particularly vulnerable to stress-related psy-
chiatric disorders due to the tendency for heightened neuro-
immune responses.
The ﬁndings reviewed here provide a framework for under-
standing how exposure to stressors may function as an additional
vulnerability factor in the development of psychiatric disorders,
particularly in females and individualswith a predisposition towards
a heightened neuroimmune response. If indeed exposure to stressors
shifts the neuroimmune microenvironment towards a primed state,
then a window of vulnerability to heightened neuroinﬂammatory
processes is opened. If a pro-inﬂammatory challenge were to occur
during this window, the heightened neuroinﬂammatory response
may lead to dysregulation of the neuroimmune microenvironment,
thereby increasing the likelihood of developingmood disorders. Pro-
inﬂammatorychallenges can takemany formssuchas theobvious, for
example bacterial or viral infection, but also the less obvious, such as
sterile injury, drugs of abuse andof course, additional stress exposure.
Therefore, understanding the mechanisms of neuroinﬂammatory
priming may lead to the development of therapeutics, which, if
applied during this window of vulnerability, could be used to
desensitize the neuroimmune microenvironment and prevent the
development of mood disorders.Acknowledgments
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